Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Wound Care Biologics Companies

ID: MRFR/MED/5101-HCR
100 Pages
Rahul Gotadki
Last Updated: February 16, 2025
Wound Care Biologics companies are pioneers in advanced wound healing solutions. Through research, development, and distribution, these organizations provide biologically derived products, contributing to accelerated and effective wound healing, improving outcomes for patients with complex wounds.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Wound Care Biologics Market
Market Size
Forecast Period2025-2035
CAGR (2025-2035)8.72%
2025 Market SizeUSD 2.50 Billion
2035 Market SizeUSD 5.77 Billion
Key Players
Organogenesis Holdings
Smith+Nephew
MiMedx Group
Integra LifeSciences
Solventum
Mölnlycke Health Care
Trends
  • Chronic-Wound Prevalence as a Structural Demand Driver
  • CMS Reimbursement Mandates Reshape Competitive Dynamics
  • FDA Antimicrobial Reclassification and Innovation Pressure
Opportunities
  • 3D Bioprinting for Patient-Specific Wound Scaffolds
  • Telehealth-Integrated Wound Monitoring Platforms
  • Emerging-Market Expansion via Lyophilized Formulations
Summary Table of Contents Segmentation Methodology Download PDF

Top Industry Leaders in the Wound Care Biologics Market

Wound Care Biologics Market
 

Latest Wound Care Biologics Companies Updates:

TideLines Medical (TSX: TLMD): Launched Artacent AC, a tri-layer skin graft designed for use in complex or difficult-to-treat wounds.

MiMedX Group (NSDQ: MDXG): Received FDA approval for PURION® processed Dehydrated Human Amnion/Chorion Membrane (dHACM) for promoting healing in acute partial-thickness burns.

Organogenesis (NASDAQ: ORGO): Announced the availability of PuraPly® Plus, a new bioabsorbable collagen matrix with additional hyaluronic acid for improved moisture retention and healing in chronic wounds.

Regenerative Biotherapeutics (OTCQB: RGBP): Initiated a Phase 2a clinical trial evaluating their investigational cell therapy, RBX2660, for treating diabetic foot ulcers.

Stemcell Technologies (TSX: SCII): Participating in a clinical trial to identify potential biomarkers for personalized treatment of chronic wounds using GABA levels in the blood.

List of Wound Care Biologics companies in the market:

  • Smith & Nephew (UK)
  • Wright Medical (US)
  • Mölnlycke Health Care AB (Sweden)
  • MiMedx Group (US)
  • Vericel Corporation (US)
  • Anika Therapeutics (US)
  • Osiris Therapeutics (US)
  • Marine Polymer Technologies, Inc. (US)
  • Kerecis (Iceland)
  • Solsys Medical (US)
  • ACell (US)

Related Reports

No regional reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035